However, simultaneous treatment of mice with PD-L1 and CTLA-4 antibodies allows for restored expression of CD80 on tumor-associated DCs, leading to increased CD28 costimulation, downstream T cell responses, and reduced overall tumor burden (6, 72, 73). This evidence concerns the gene CD28 and neoplasm.